Epigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area.

TitleEpigenetic basis of opiate suppression of Bdnf gene expression in the ventral tegmental area.
Publication TypeJournal Article
Year of Publication2015
AuteursKoo, JWook, Mazei-Robison, MS, LaPlant, Q, Egervari, G, Braunscheidel, KM, Adank, DN, Ferguson, D, Feng, J, Sun, H, Scobie, KN, Damez-Werno, DM, Ribeiro, E, Peña, CJensen, Walker, D, Bagot, RC, Cahill, ME, Anderson, SAnn R, Labonté, B, Hodes, GE, Browne, H, Chadwick, B, Robison, AJ, Vialou, VF, Dias, C, Lorsch, Z, Mouzon, E, Lobo, MKay, Dietz, DM, Russo, SJ, Neve, RL, Hurd, YL, Nestler, EJ
JournalNat Neurosci
Volume18
Pagination415-22
Date Published2015 Mar
ISSN1546-1726
Abstract

Brain-derived neurotrophic factor (BDNF) has a crucial role in modulating neural and behavioral plasticity to drugs of abuse. We found a persistent downregulation of exon-specific Bdnf expression in the ventral tegmental area (VTA) in response to chronic opiate exposure, which was mediated by specific epigenetic modifications at the corresponding Bdnf gene promoters. Exposure to chronic morphine increased stalling of RNA polymerase II at these Bdnf promoters in VTA and altered permissive and repressive histone modifications and occupancy of their regulatory proteins at the specific promoters. Furthermore, we found that morphine suppressed binding of phospho-CREB (cAMP response element binding protein) to Bdnf promoters in VTA, which resulted from enrichment of trimethylated H3K27 at the promoters, and that decreased NURR1 (nuclear receptor related-1) expression also contributed to Bdnf repression and associated behavioral plasticity to morphine. Our findings suggest previously unknown epigenetic mechanisms of morphine-induced molecular and behavioral neuroadaptations.

DOI10.1038/nn.3932